PEAK6 Group’s Heron Therapeutics HRTX Stock Holding History

PEAK6 Group’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-9,000	Closed	-$220K	–	4971
2015 Q3	$220K	Buy	+9,000	New	+$300K	﹤0.01%	3651

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PEAK6 Group's HRTX Position: Q4 2015 in Review

PEAK6 Group sold out of Heron Therapeutics (HRTX) in Q4 2015, closing a stake of 9,000 shares — an estimated $220K sold.

PEAK6 Group first reported a position in HRTX in Q3 2015 and held it in 1 quarter. The position peaked at $220K in Q3 2015. 107 funds tracked by Wall St. Rank hold HRTX as of Q4 2015.

PEAK6 Group reported no remaining Heron Therapeutics position as of Q4 2015 after selling out during the quarter.
PEAK6 Group sold 9,000 Heron Therapeutics shares in Q4 2015, an estimated $220K.
PEAK6 Group first reported a position in Heron Therapeutics in Q3 2015 and held it in 1 quarter.
PEAK6 Group's Heron Therapeutics position peaked at $220K in Q3 2015.
107 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2015.

Based on PEAK6 Group's 13F filing for Q4 2015, filed 16 Feb 2016.